Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence

Gómez-Río, Manuel; Rodrı́guez-Fernández, Antonio; Ramos-Font, C.; López-Ramírez, Escarlata; Elvira, J.M. Llamas

doi:10.1007/s00259-007-0661-5

Cited by 64 publications

(36 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When considering both low-and high-grade gliomas, [16][17][18][19][21][22][23]27,32,33,40,41 sensitivity ranged between 0.23 and 0.95 and specificity ranged between 0.17 and 1.0. For high-grade gliomas, [16][17][18][19]27,34,35,39,41 sensitivity ranged between 0.18 and 1.00 and specificity ranged 0.25 and 1.0. Studies including both low-and high-grade gliomas had a summary sensitivity of 0.77 (95% CI, 0.66 -0.85) and a summary specificity of 0.78 (95% CI, 0.54 -0.91), corresponding to a positive likelihood ratio of 3.4 (95% CI, 1.6 -7.5) and a negative likelihood ratio of 0.30 (95% CI, 0.21-0.43) (Fig 2).…”

Section: Sensitivity Specificity Likelihood Ratios and Summary Rocmentioning

confidence: 99%

Diagnostic Accuracy of PET for Recurrent Glioma Diagnosis: A Meta-Analysis

Nishizaki

Dahabreh

Terasawa

2012

AJNR Am J Neuroradiol

155

105

View full text Add to dashboard Cite

BACKGROUND AND PURPOSE:Studies have assessed PET by using various tracers to diagnose disease recurrence in patients with previously treated glioma; however, the accuracy of these methods, particularly compared with alternative imaging modalities, remains unclear. We conducted a meta-analysis to quantitatively synthesize the diagnostic accuracy of PET and compare it with alternative imaging modalities.

show abstract

Section: Sensitivity Specificity Likelihood Ratios and Summary Rocmentioning

confidence: 99%

Diagnostic Accuracy of PET for Recurrent Glioma Diagnosis: A Meta-Analysis

Nishizaki

Dahabreh

Terasawa

2012

AJNR Am J Neuroradiol

155

105

View full text Add to dashboard Cite

show abstract

“…& Differences in glucose metabolism between tumor and treatment necrosis have been demonstrated on flurodeoxyglucose positron emission tomography (FDG-PET) [57,58], although the diagnostic accuracy for differentiating tumor from necrosis is limited due to the high background uptake and lower imaging resolution. Amino acid radiotracers have the advantage of high lesion to background contrast due to their selective uptake by proliferating tumor tissues.…”

Section: Positron Emission Tomographymentioning

confidence: 99%

How Treatment Monitoring Is Influencing Treatment Decisions in Glioblastomas

Neagu

Huang

Reardon

et al. 2015

Curr Treat Options Neurol

View full text Add to dashboard Cite

Glioblastoma (GBM), the most common malignant primary tumor in adults, carries a dismal prognosis with an average median survival of 14-16 months. The current standard of care for newly diagnosed GBM consists of maximal safe resection followed by fractionated radiotherapy combined with concurrent temozolomide and 6 to 12 cycles of adjuvant temozolomide. The determination of treatment response and clinical decision-making in the treatment of GBM depends on accurate radiographic assessment. Differentiating treatment response from tumor progression is challenging and combines long-term follow-up using standard MRI, with assessing clinical status and corticosteroid dependency. At progression, bevacizumab is the mainstay of treatment. Incorporation of antiangiogenic therapies leads to rapid blood-brain barrier normalization with remarkable radiographic response often not accompanied by the expected survival benefit, further complicating imaging assessment. Improved radiographic interpretation criteria, such as the Response Assessment in Neuro-Oncology (RANO) criteria, incorporate non-enhancing disease but still fall short of definitely distinguishing tumor progression, pseudoresponse, and pseudoprogression. With new evolving treatment modalities for this devastating disease, advanced imaging modalities are increasingly becoming part of routine clinical care in a field where neuroimaging has such essential role in guiding treatment decisions and defining clinical trial eligibility and efficacy.

show abstract

“…Diagnosis of brain tumor recurrence has been an imaging challenge also for PET. Although initial reports for 18 F-FDG were encouraging (Di Chiro et al, 1988), more recent studies questioned its diagnostic accuracy, which was found considerably inferior to that of 201 Tl SPECT in several series (Kahn et al, 1994;Gómez-Río et al, 2008). A significant disadvantage of 18 F-FDG derives from its physiological uptake in the glucose-metabolizing normal brain.…”

Section: Other Metabolic Imaging Modalities: Petmentioning

confidence: 99%